Equities research analysts expect Transenterix Inc (NYSE:TRXC) to announce earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Transenterix’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.10). Transenterix also posted earnings per share of ($0.11) in the same quarter last year. The business is expected to announce its next quarterly earnings report on Friday, August 4th.
On average, analysts expect that Transenterix will report full-year earnings of ($0.42) per share for the current year, with EPS estimates ranging from ($0.45) to ($0.38). For the next financial year, analysts forecast that the business will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Transenterix.
Transenterix (NYSE:TRXC) last released its quarterly earnings data on Monday, March 6th. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01.
Several research analysts recently weighed in on TRXC shares. B. Riley reaffirmed a “buy” rating and set a $2.75 target price on shares of Transenterix in a research note on Sunday, March 12th. Zacks Investment Research raised Transenterix from a “sell” rating to a “hold” rating in a research note on Tuesday, January 24th. Finally, Raymond James Financial, Inc. cut Transenterix from an “outperform” rating to a “mkt perform” rating in a research note on Thursday, January 19th.
Shares of Transenterix (NYSE:TRXC) opened at 0.5281 on Wednesday. Transenterix has a 52-week low of $0.52 and a 52-week high of $2.33. The company has a 50 day moving average of $0.94 and a 200 day moving average of $1.28. The stock’s market capitalization is $65.29 million.
TRADEMARK VIOLATION NOTICE: This report was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/06/16/zacks-analysts-expect-transenterix-inc-trxc-to-announce-0-11-earnings-per-share-updated-updated-updated.html.
A hedge fund recently raised its stake in Transenterix stock. State Street Corp boosted its stake in shares of Transenterix Inc (NYSE:TRXC) by 14.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 849,678 shares of the medical instruments supplier’s stock after buying an additional 106,040 shares during the period. State Street Corp owned 0.74% of Transenterix worth $1,104,000 as of its most recent SEC filing.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.